RxDoctor Payments Data

Rikki Enzor, MD

Ophthalmology · Saint Joseph, MINPI 1639528599

Payments from drug & device makers

$4,603in general payments, 2019–2025

Across 43 payments — averaging $107.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Sight Sciences, Inc.$525
  • Alcon$494
  • Bausch & Lomb Americas Inc.$107
  • Ivantis, Inc$27
  • NEW World Medical,inc.$19

What the payments were for

  • Consulting fees$95021%
  • Travel & lodging$1,58134%
  • Food & beverage$1,95843%
  • Education$1132%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)18$3,432
Sight Sciences, Inc.7$525
Alcon15$494
Bausch & Lomb Americas Inc.1$107
Ivantis, Inc1$27
NEW World Medical,inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,603 in reported general payments places this provider in the 80th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$218,481
Medicare patients
485
Services billed
2,135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost170$65,356
RhopressaNetarsudil Mesylate91$37,559
RestasisCyclosporine30$22,836
LumiganBimatoprost39$18,092
SimbrinzaBrinzolamide/Brimonidine Tart60$15,575
Prednisolone Acetate405$11,853
Latanoprost1,188$10,286
VyzultaLatanoprostene Bunod18$8,121
Restasis MultidoseCyclosporine13$7,559
Brimonidine Tartrate316$5,792
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat374$5,489
CombiganBrimonidine Tartrate/Timolol11$4,721
Ketorolac Tromethamine283$4,514
Dorzolamide-TimololDorzolamide/Timolol/Pf29$3,233
TafluprostTafluprost/Pf17$2,897

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Restasis Multidose, Combigan$3,432$53,20993 claims
AlconSimbrinza$494$15,57560 claims
Bausch & Lomb Americas Inc.Vyzulta$107$8,12118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Saint Joseph

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →